These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 32389016)

  • 1. Torsade de pointes in initiating hemodialysis: a case report.
    Yang JA; Choi HS; Bae EH; Ma SK; Kim SW; Kim CS
    Ann Palliat Med; 2020 May; 9(3):1264-1268. PubMed ID: 32389016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.
    Hii JT; Wyse DG; Gillis AM; Duff HJ; Solylo MA; Mitchell LB
    Circulation; 1992 Nov; 86(5):1376-82. PubMed ID: 1423949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
    Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
    Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of amiodarone-induced torsade de pointes by landiolol in a patient with atrial fibrillation-mediated cardiomyopathy.
    Takahashi K; Yamashita M; Sakaue T; Enomoto D; Uemura S; Okura T; Ikeda S; Takemoto M; Utsunomiya Y; Hyodo T
    Ann Noninvasive Electrocardiol; 2021 Nov; 26(6):e12842. PubMed ID: 33755267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.
    Skanes AC; Morton BC; Green MS; Tang AS
    Can J Cardiol; 1997 Apr; 13(4):383-6. PubMed ID: 9141970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibutilide-induced long QT syndrome and torsade de pointes.
    Gowda RM; Punukollu G; Khan IA; Patlola RR; Tejani FH; Cosme-Thormann BF; Vasavada BC; Sacchi TJ
    Am J Ther; 2002; 9(6):527-9. PubMed ID: 12424513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy.
    Mattioni TA; Zheutlin TA; Sarmiento JJ; Parker M; Lesch M; Kehoe RF
    Ann Intern Med; 1989 Oct; 111(7):574-80. PubMed ID: 2774388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced torsade de pointes.
    Raehl CL; Patel AK; LeRoy M
    Clin Pharm; 1985; 4(6):675-90. PubMed ID: 2416504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Torsade de pointes induced by intravenous and long-term oral amiodarone therapy in a patient with dilated cardiomyopathy.
    Yamada S; Kuga K; Yamaguchi I
    Jpn Circ J; 2001 Mar; 65(3):236-8. PubMed ID: 11266201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Torsade de pointes induced by intravenous amiodarone therapy accompanied by marked augmentation of the transmural dispersion of repolarization in a patient with tachycardia-induced-cardiomyopathy.
    Yonai R; Kawabata M; Maeda S; Kawashima T; Tsuda Y; Nakasone T; Nakane H; Hirao K
    Ann Noninvasive Electrocardiol; 2021 May; 26(3):e12810. PubMed ID: 33070441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Amiodarone therapy after sotalol-induced torsade de pointes: prolonged QT interval and QT dispersion in differentiation of pro-arrhythmic effects].
    van de Loo A; Klingenheben T; Hohnloser SH
    Z Kardiol; 1994 Dec; 83(12):887-90. PubMed ID: 7846927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QT interval prolongation, torsade de pointes and renal disease.
    Patanè S; Marte F; Di Bella G; Currò A; Coglitore S
    Int J Cardiol; 2008 Nov; 130(2):e71-3. PubMed ID: 18255176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Torsade de pointes" during amiodarone infusion in a cirrhotic woman with a prolonged QT interval.
    Di Micoli A; Zambruni A; Bracci E; Benazzi B; Zappoli P; Berzigotti A; Zoli M; Bernardi M; Trevisani F
    Dig Liver Dis; 2009 Jul; 41(7):535-8. PubMed ID: 18294935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Torsade de pointes tachycardia in a patient on dronedarone therapy.
    Huemer M; Sarganas G; Bronder E; Klimpel A; Garbe E; Haverkamp W
    Pharmacotherapy; 2015 May; 35(5):e61-5. PubMed ID: 25823967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiarrhythmic drugs and torsade de pointes.
    Lazzara R
    Eur Heart J; 1993 Nov; 14 Suppl H():88-92. PubMed ID: 8293758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations.
    Carlsson L; Abrahamsson C; Andersson B; Duker G; Schiller-Linhardt G
    Cardiovasc Res; 1993 Dec; 27(12):2186-93. PubMed ID: 8313427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis.
    Daya SK; Gowda RM; Khan IA
    Am J Ther; 2004; 11(1):77-9. PubMed ID: 14704599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time- and rate-dependent alterations of the QT interval precede the onset of torsade de pointes in patients with acquired QT prolongation.
    Gilmour RF; Riccio ML; Locati EH; Maison-Blanche P; Coumel P; Schwartz PJ
    J Am Coll Cardiol; 1997 Jul; 30(1):209-17. PubMed ID: 9207644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haloperidol-induced torsade de pointes.
    O'Brien JM; Rockwood RP; Suh KI
    Ann Pharmacother; 1999 Oct; 33(10):1046-50. PubMed ID: 10534216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Torsades de pointes and QT prolongation due to a combination of loratadine and amiodarone.
    Atar S; Freedberg NA; Antonelli D; Rosenfeld T
    Pacing Clin Electrophysiol; 2003 Mar; 26(3):785-6. PubMed ID: 12698686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.